University of London

Queen Mary & Westfield College

Ugp Therapeutics, Inc.

Resother Pharma Aps

Mauro Perretti

Fulvio D'Acquisto

Nozer M Mehta

Angelo P Consalvo

Jesmond P Dalli

Jesmond Dalli

Roderick John Flower

The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.

Methods of treating obsessive compulsive disorder (OCD) or anxiety using an antibody that binds to annexin-1

The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG.A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.

Annexin 1 antibody

Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.

Anti-inflammatory pharmaceutical products

The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease.

Growing community of inventors

London, United Kingdom

Mauro Perretti